GlassScriptPhysician profile
Kay Siglos
NPI 1396053104
$589.16
in general payments reported to CMS, 2019-2025
11 companies · $55.81 in 2025
The $55.81 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.04 · 2023: $371 · 2024: $120 · 2025: $55.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $164.02 | 2023 | Endurant Iis |
| Glaxosmithkline, LLC. | $122.55 | 2023 | Bexsero |
| Exact Sciences Corporation | $61.35 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $47.55 | 2023-2024 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $42.61 | 2024 | Hyqvia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.36 | 2023 | Trulance, Xifaxan |
| Dynavax Technologies Corporation | $28.46 | 2025 | Heplisav-B |
| Dexcom, INC. | $27.84 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $22.65 | 2024 | Uptravi, Opsumit |
| Lilly USA, LLC | $22.57 | 2023 | Mounjaro |
| Almatica Pharma LLC | $14.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kay Siglos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.